Vitruvias Therapeutics, LLC and Sunny Pharmtech Inc. announced that they have formed a strategic partnership to co-develop a varied portfolio of generic drugs. The agreement will leverage the research, development, and distribution capabilities of each company to quickly and efficiently develop and commercialize generic products in markets that currently exceed $400 mil. Each company will have a 50% stake in product portfolio, and the first ANDA will be tentatively filed in the fourth quarter of 2015.